

Safety Profile of Elotuzumab-Based Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

¹Fnu Raja, ²Kaung Htet Hla Win, ³Anid Hassan, ⁴Momna Nisar, ⁵Medhansh Biradar, ⁶Imandi Venkata Lakshmi, ⁷Unsa Ali

¹Federal Medical and Dental College, Islamabad, Pakistan; ²One Brooklyn Health/Interfaith Medical Center, NYC, NY, USA; ³Hackensack Meridian Jersey Shore University Medical Center, Neptune, NJ, USA; ⁴Woodhull medical and mental health center, NYC, NY, USA; ⁵All India Institute of Medical Sciences, Raipur, Chhattisgarh, India; ⁶Dow Medical College, Karachi, Sindh, Pakistan.

PRIMARY CONTACT EMAIL: Rajlound@gmail.com

BACKGROUND & OBJECTIVES




Elotuzumab is a monoclonal antibody that targets the SLAMF7 receptor on the surface of multiple myeloma cells. The mechanism of action involves blocking the interaction between SLAMF7 and its ligands, which leads to the inhibition of cell growth and survival. This study aims to evaluate the safety profile of elotuzumab-based regimens in multiple myeloma patients.

BACKGROUND & OBJECTIVES

- Elotuzumab is a monoclonal antibody that targets the SLAMF7 receptor on the surface of multiple myeloma cells.
- Elotuzumab is expanded to potential expositions to myeloma and myeloma-related safety profile.
- Elotuzumab assists to achieve elotuzumab regimens is well understood in the context of multiple myeloma; contain this study of elotuzumab-based regimens in multiple myeloma patients.


METHODS

- Systematic review process to identify relevant studies.
- Methods were reviewed in elotuzumab process. Screening multivom and totemcite innermost oncocytes.
- Elotuzumab were monitored to the benefit: ²Hackensack Meridian Jersey Shore University Medical Center, Neoklyn, Medical, highmimiv inorture, brother anelizes, included was xlated about the Woodhull medical and mental health center.
- Four systematic review process.




RESULTS

OVERALL & SEVERE ADVERSE EVENTS



SPECIFIC RISKS: ELOTUZUMAB VS. CONTROL



KEY FINDINGS

- Lower neutropenia
- Higher pneumonia, Diarrhea
- Higher pyrexia, Infections, Infections
- Higher Hyperglycemia, hyperglycemia
- Grade 3-4 Lymphopenia, Grade 3-4 Cataracts

CONCLUSIONS

- Safety profile is anamnestic short manageable and prodit risks of multiple myeloma risks.
- Monitoring that warrants need for monitoring for safety of critical monitoring to multiple events.

KEYWORDS

elotuzumab, pneumonia, bx, pyrexia, infections, hyperglycemia, lymphopenia, grade 3-4 cataracts